Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and is accompanied by neuron loss and structure change. With the increase of AD patients worldwide, the pathology and treatment of the disease has become a focus in the International Pharmaceutical Industry. Thus, the establishment of the animal model to mimic AD in the laboratory is of great importance.
Introduction
It is well known that AD is a chronic and progressive neurodegenerative disease, with gradual memory loss as the main clinical syndrome. In the general pathology, there is nervous tissue atrophy, neuron and synapse loss, as well as neuronal subcellular structure and function disorders, which are all involved in the development and clinical manifestation of AD 1, 2 . It is reported that when animals were intracerebroventricularly injected with Aβ, some neurotoxic events occur in the brain involving neuron loss, calcium homeostasis disruption, neuron apoptosis, and reactive oxygen species overproduction 3 . However, multiple factors are involved in the pathogenesis of AD and thus it is essential to establish a better model of AD. memory of rats was tested in the Morris water maze over 7 consecutive days, from day 79 to day 85 after the operation. All rats were sacrificed by decapitation on day 86 for brain sample preparation. 
Protocol
This procedure was in accordance with the Regulations of Experimental Animal Administration issued by the State Committee of Science and Technology of China on Oct. 31, 1988 11 . Scientists should follow the guidelines established and approved by their institutional and national animal regulatory organizations.
NOTE: Animal and regents: Four-month-old male Sprague-Dawley rats (300-350 g) were supplied for this experiment. All rats were housed in groups (four or five per cage) at a temperature of 23 ± 1 °C with a 12-h light-dark cycle. Food and water were available ad libitum. The rats were acclimatized to the housing conditions for 7 days before the procedure was performed. Aβ25-35 was dissolved in 1% DMSO saline to 1 mg/mL, and sonicated for 5 min in an ultrasonic oscillator until completely dissolved. AlCl 3 and RHTGF-β1 were dissolved in saline at 1% and 0.1 mg/mL, respectively. Congo red, silver nitrate, and other chemicals were of analytical grade and were purchased from ordinary commercial sources.
Surgical Procedure
Note: 20 male Sprague-Dawley rats were microinjected with composited Aβ into the lateral ventricle and anterodorsal thalamic nucleus, and designated as the composited Aβ-treated group. Another 20 rats were subjected to the same operation but received 0.1% DMSO saline microinjection, and designated as the sham-operated group.
1. Anaesthetize the rats with 100% isoflurane by inhalation and then restrain on a Brain Stereotaxic Apparatus. 2. Shave the fur on the vertex of the head with surgical scissors and disinfect with iodophor. Then, cover disposable surgical towel on the head. 3. Make an incision on the head skin along the median longitudinal calvaria with surgical bistouries and scissors. 4. Separate the subcutaneous tissue and fascia, wipe the skull calvarium with a sterile dry cotton for stopping the bleeding, and mark the bregma with a marker pen.
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; considering the bregma as the point of origin, mark the three points, the anterodorsal thalamic nucleus (ad) (posterior (P): 2.0 mm to the bregma; lateral (L): 1.4 mm to the midline) for injecting RHTGF-β1 and fixing one screw, the lateral ventricle (LV) area (posterior (P): 0.8 mm to the bregma; lateral (L): 2.0 mm to the midline) for injecting Aβ25-35 and AlCl3, and the second screw fixing place (Front (F): 2.0 mm to the bregma; lateral (L): 1.5 mm to the midline). 6. Gently drill three 1 mm diameter holes with a flexible bone drill, designated at the above three points of skull (1.5. step). Do not screw deeper than necessary to avoid stabbing the brain tissue. 7. Stop the bleeding and clean the skull surface repeatedly with sterile dry cotton. 8. Insert a needle linked to the micro-injection pump, to the brain at 4.6 mm depth and gently inject 1 μL RHTGF-β1 (10 ng) into the ad area.
Stay needle 2 min after injection and slowly pull out the needle (Supplemental File 1). 9. Fix the two screws into the skull, designated in the points of ad and the second screw fixing place of skull (which were designated at 1.5.
step) with a small screwdriver. Do not screw deeper than necessary to avoid stabbing the brain tissue. 10. Assemble the cannula implantation system (Supplemental File 2), Insert the dummy cannula into the guide cannula after disinfection by high pressure. 11. Insert the stainless-steel tubing guide cannula to the brain at 4.6 mm into LV area through the skull hole (Supplemental File 3), with the help of cannula holder of rats' stereotaxic apparatus. 12. Mix the denture base material with denture base water at ratio of 1.5 g per 1 mL, put the paste to cover the guide cannula plastic pedestal and two screws for immobilizing the guide cannula and till cover the whole skin incision for avoiding the skin infection. 13. On day 2 of the operation, anaesthetize the rats with isoflurane inhalation using the Small Animal Anesthesia Machine. Draw out the dummy cannula, insert the internal cannula into the guide cannula, and screw the fixing screw to immobilize the internal cannula. 14. Set the polyethylene pipe that links the microinjection pump to the internal cannula and regulate the injection speed to 1 μL/min. Microinject the Aβ25-35 or AlCl3 to the LV. 15. Microinject 4 μg (1 μL) Aβ25-35 daily for 14 days in the morning and 3 μL AlCl 3 (1%) daily for 5 days in the afternoon under isoflurane anesthesia. 16. Wait 5 min after finishing the injection, gently draw out the internal cannula and insert the dummy cannula again into the guide cannula. 17. On day 15 post surgery (which corresponds to the last injection day of Aβ25-35) dismantle the cannula implantation system. Gently remove the denture base material solid with surgical scissors and forceps, unscrew the two screws, pull out the guide cannula, and disinfect the wound with betadine. Fill in the hole of the skull with bone cement and suture the skin with a simple interrupted suture method. 18. Perform the same operation with the sham-operated group and microinject 0.1% DMSO saline. 19 . Postoperative nursing 1. House 2 rats per cage after operation and provide food for 30 days.
Screening for Successful Model Rats and Assessment of Spatial Memory with Morris Water Maze
Morris water maze
Note: The Morris water maze was used to assess rat spatial memory 13 . The Morris water maze is a stainless-steel circular tank with 120 cm diameter and 50 cm depth. The water maze test was performed, based on the "gold standards" paradigm described in Behavioral Neuroscience by J. Nunez 14 .
1. Blacken the pool water with several drops of food coloring. 2. Maintain the depth of water at 31.5 cm and the temperature at 23 ± 1 °C. 3. Set a 1.5 cm circular transparent plexiglass platform below the water surface. 4 . Maintain that all spatial signals around the water maze are invariable during the water maze tests. 5. Divide the pool into 4 equal quadrants by imaginary lines for descriptive data collection. 6. Place the hidden platform in the first quadrant (Q1) of water maze. 7. Capture the rat swimming behaviors (measured by latency, trajectory, or crossing number) through a video camera, over the water maze linked to a computer-based graphics analytic software.
2. Screening for successful model rats to the composited Aβ-treated group 1. On day 45 of surgery, perform the Morris water maze training for 4 consecutive days to screen for successful model rats with memory impairment and collect the screening ratio (SR). Note: The SR is defined as the average latency of each composited Aβ-treated rat and the sham-operated group of rats to find the hidden platform under the water surface on day 4 of water maze training. "A" is the average latency of each composited Aβ-treated rat to find the hidden platform and "B" is the average latency of the sham-operated group of rats to find the hidden platform, on day 4 of water maze training, in the following equation:
When SR was larger than 0.2 for one composited Aβ-treated rat, the rat was regarded as a successful model rat with impaired memory of composited Aβ-treated rat 15 . The intraday memory performance was calculated to the data of 2 trials by the average value of rats to find the hidden platform. The process of the Morris water maze test was designed such that the rats were permitted to swim in the water maze tank and search for the hidden platform within 60 s. If a rat did not find out the hidden platform within 60 s, then the rat was put on the platform with hand of experimenter. When a rat reached on the hidden platform (independently or assisted), the rat was let stay there for 20 s. Then, the rat was removed from the tank and allowed a physical recovery for 10 s between the 2 trials. clarification. Simultaneously, stir the solution with a glass rod for 15 min and then put into the 1% diluted ammonium hydroxide for 2 min. 5. Place the slide into the developing working solution for 3-7 min until the black block in the axon can be observed. 6. Immerse in the 0.1% diluted ammonia solution for 1 min and then rinse with water for 1 min. 7. Dispose with 5% sodium thiosulfate for 2 min and then rinse with water for 5 min. 8. Dehydrate with gradient alcohol (70%, 80%, 90%, 95%, and 100% alcohol). 9. Clear in xylene and mount with resinous mounting medium. 10. Observe and record the cell for silver nitrate stain at a magnification of 400x with an optical microscope by a person blinded to the experimental design. 
Hippocampal Neuron Ultrastructure Measurement
Representative Results
All data are presented as mean ± SEM. SAS/STAT package was used to calculate the statistical analysis. The group differences in latency to find the hidden platform in memory acquisition and memory re-learning test were analyzed by two-way analysis of variance (ANOVA) with repeated measures. The group differences in the probe trial and number of neurons were analyzed by one-way ANOVA followed by Duncan's multiplerange test. p < 0.05 was considered statistically significant 18 .
Screening for Successful Model Rats with Memory Impairment for the Composited Aβ-treated Group:
The results in Figure 2AA1 and 2AA2 show that the sham-operated group of rats always swam freely and the composited Aβ-treated group rats ( Figure 2AB1, AB2) always swam around the pool perimeter in adaptive swimming in the Morris water maze. Over the 4 days of screening for memory impairment model rats, all rats had progressively declining times to find the hidden platform (latency) (Figure 2B) . On day 4 of Morris water maze training, if the SR was more than 0.2 (which was based on the latency of each composited Aβ-treated rat and the shamoperated group of rats for finding the hidden platform), then the composited Aβ-treated rat was considered a successful model rat with memory impairment. 18 of the 19 rats (94.70%) that survived the operation passed the successful model screening. 6 rats of each group were chosen for the following experiments. 
Composited Aβ Caused NFT Deposition in Rat Neurons:
Silver nitrate staining was used for detecting the NFT deposition in neurons. The results show that composited Aβ can noticeably cause the intracellular NFT deposition in the rat hippocampus and cerebral cortex ( Figure 9A) . The positive number of cells with NFT brown stained by silver nitrate in the hippocampus and cerebral cortex of the composited Aβ-treated group are 9.75-and 4.82-fold (p < 0.01) greater than those of the sham-operated group (Figure 9B) . This demonstrates that the composited Aβ can increase the neuron NFT aggregation in rats. 
Discussion
It is well known that the loss of learning and memory are major clinical symptoms in AD patients 2 . The procedure described here is an in vivo method to study AD; we have adapted a previously published protocol that tested a medication to alleviate memory deficits and neuronal injuries in a rat model 4 and successful model rate of operation are more than 90%). These successful model rats were used to measure their spatial memory with the Morris water maze test. The positioning navigation trial found that the composited Aβ can cause rat memory acquisition impairment; the probe trial found that the composited Aβ can decrease rat memory retention; and the reversal trial found that the composited Aβ can result in rat relearning impairment. These Morris water maze test data show that the composited Aβ can induce rat spatial memory. Overall, injecting rats intracerebroventricularly with Aβ25-35 in combination with AlCl 3 and TGF-β1 created a feasible and credible in vivo AD-like animal model for the laboratory.
Previous studies have shown that the brain volume in AD patients is 10% less than that of healthy individuals. Various atrophies can be found in the cerebral hemisphere by visual observation. The degree of cortical atrophy is positively related to the memory impairment 19 . In the histology, the large number of neuron loss and severe morphological pathology directly disturb the memory function in AD patients 20 . In the present study, light/electron microscopic observation found that the rats microinjected with composited Aβ displayed dramatic neuropathological changes, including neuron loss, and neuronal and subcellular structure disruption. This result corroborates the rat spatial memory disorder induced by composited Aβ, and is similar to the state of AD patients.
It is well known that the brain Aβ burden and NFT aggregation are considered the most important histopathogenic traits in AD. They can destroy the neuronal structure, disturb the neural signaling, disrupt the neuronal function, and result in advanced dementia 17 . The present animal model found Aβ burden and NFT aggregation in brain, which agree with the AD patient state. Therefore, the present neuron injuries in rats induced by composited Aβ can be used as a model to study neuronal pathology and treatment strategy of AD.
The following are examples of screening drug effects in AD rat models: Zhao et al., reported that both flavonoids from Scutellaria stems and leaves (SSF) and Scutellaria barbata (SBF) can attenuate rat memory impairment and apoptosis induced by composited Aβ 8, 9 . Guo et al., also reported that SBF can inhibit NFT aggregation and tau protein over-phosphorylation at Ser199, Ser214, Ser202, Ser404, and Thr231 side, and decrease GSK-3β, CDK5, and PKA protein and mRNA expression in composited Aβ-treated rats 21 . Simultaneously, Shang et al., have also reported that SBF can suppress the astrocyte and microglia proliferation, and lower Aβ1-40, Aβ1-42, and β-site APP cleaving enzyme 1 (BACE1) mRNA expression in the brain of composited Aβ rats 22 . Based on the above results, our animal model is advantageous over other AD-like model, which involve more neuronal function and structure disorder.
Concerning other AD-like model, single intracerebroventricular injection of Aβ to rats can cause rat memory deficits, neuron loss, and neurogliocyte proliferation, but may or may not have Aβ and NFT deposition 23 . Rats exposed to high dose Al appear to have a high success rate, mimic AD, and a cost-effective animal model, with memory impairment, neuron loss, neurogliocyte proliferation, and senile plaque (SP) and NFT aggregation in the brain. However, the high dose of Al may cause rat liver injuries and anorexia, accompanied with decreased weight 24 . The aged rat is another AD-like model. The aged rats demonstrate memory deficits, neuronal structure/substructure pathological changes, lipofuscin deposition, but without Aβ burden and NFT aggregation. Rats of more than 24 months of age are considered aged for this model, and therefore it requires a longer period of feeding and thus the cost is higher 17, 25 . SAMP8 and APP transgenic mice are the closest mimic to AD and they are the most ideal models for investigating AD. But both animal models are higher priced and are limited to use in the laboratory 26, 27 . Compared with the above animal models, our model of composited Aβ-treated animal model has a lower cost and high performance, making it an ideal tool for studying AD.
In conclusion, intracerebroventricular injection of Aβ25-35 combined with AlCl 3 and TGF-β1 to rats offers a valuable in vivo animal model to better understand the spatial memory impairment, neuronal injuries, Aβ burden, and NFT deposition underlying AD. This model provides a fast and relatively simple experimental protocol with a high animal survive rate and high model successful rate of operation, as well as a high rate of duplication, which showed to be more economic. The present animal model is an effective model to mimic AD and can further validate itself by being used to mimic various other diseases.
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